Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2024 | EAZ171: assessing the best taxane for peripheral neuropathy reduction in breast cancer

Tarah Jean Ballinger • 1 Jun 2024
ASCO 2024
General Docetaxel Paclitaxel
EAZ171

Tarah Jean Ballinger, MD, Indiana University School of Medicine, Indianapolis, IN, discusses findings from the EAZ171 trial (NCT04001829), which addresses racial disparities in treatment-induced peripheral neuropathy (TIPN) among Black women receiving weekly paclitaxel versus every three-week docetaxel for early-stage breast cancer. Black women on weekly paclitaxel experienced higher TIPN rates and dose reductions, suggesting docetaxel as a preferred treatment to enhance tolerance and potentially improve outcomes for Black women. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Honoraria – Tersera
Consulting or Advisory Role – Medscape

More from Tarah Jean Ballinger

Treatment strategies for chemotherapy-induced peripheral neuropathy
0:56
Treatment strategies for chemotherapy-induced peripheral neuropathy
Tarah Jean Ballinger • 31 May 2024
Managing treatment-induced peripheral neuropathy in Black patients with breast cancer
0:51
Managing treatment-induced peripheral neuropathy in Black patients with breast cancer
Tarah Jean Ballinger • 31 May 2024

Related Videos

AI governance and validation in robotic cancer surgery
1:12
AI governance and validation in robotic cancer surgery
Marie Hanaoka • 1 Jul 2026
Does toxicity differ between patients treated with SABR for one versus five lesions?
0:39
Does toxicity differ between patients treated with SABR for one versus five lesions?
Robert Olson • 16 May 2026
5-year toxicity following SABR: insights from the SABR-5 trial
0:42
5-year toxicity following SABR: insights from the SABR-5 trial
Robert Olson • 16 May 2026
How should results from the SABR-5 trial guide future SABR studies?
1:05
How should results from the SABR-5 trial guide future SABR studies?
Robert Olson • 16 May 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals